Houston – November 05, 2026 -- ImmunoGenesis will present IND-enabling data for IMGS-203, its novel STING agonist for recurrent glioblastoma (GBM), at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, running November 4-8 at the Phoenix Convention Center in Arizona.
ImmunoGenesis targets recurrent glioblastoma with IMGS-203 as its first clinical indication
The company plans to advance IMGS-203 into clinical development first for recurrent GBM, which it describes as an aggressive brain cancer with limited therapeutic options and significant unmet medical need. IMGS-203 is a Stimulator of Interferon Genes (STING) agonist designed to stimulate antitumor immune responses. The presentations will cover both the IND-enabling activities and the therapeutic potential of the candidate, in poster and oral formats.
IMGS-001 remains the lead program in a phase 1a/b trial for immune-excluded tumors
The clinical-stage company's lead asset, IMGS-001, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2. It is in a phase 1a/b trial for immune-excluded tumors, which ImmunoGenesis says account for more than half of all cancers.
ImmunoGenesis is building a multi-mechanism strategy to overcome immune exclusion and enable a robust immune response in the tumor microenvironment. IMGS-203 adds a preclinical STING-based asset to that pipeline.